Revvity Acquires Human Cell Design
Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 11, 2026
The deal modestly strengthens Revvity's life sciences tools franchise in metabolic disease research, a growing area given demand for GLP-1-related discovery capabilities, but the undisclosed financial terms and small scale of the target limit near-term earnings impact. Market reaction was slightly negative, with RVTY shares reportedly down 2.3% since the announcement, reflecting limited immediate financial accretion and integration risk.
Revvity, Inc. (NYSE: RVTY) announced on September 9, 2026 that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models, including its flagship EndoC-betaH5 model, to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. HCD also offers specialized media and reagents, preclinical research services and its proprietary NatLine cell-line development platform. The transaction is expected to close in Q4 2026 and is subject to customary closing conditions, including required regulatory approvals. Financial terms were not disclosed. Revvity CEO Prahlad Singh Patel said HCD brings differentiated human cell models that complement Revvity's broad portfolio of technologies supporting drug discovery and development. HCD founder and president Guillaume Costecalde said joining Revvity is expected to bring the company's human cell models and NatLine technology to a broader global customer base. Revvity reported 2025 revenue of $2.9 billion, employs approximately 11,000 people and is part of the S&P 500 index. Following the announcement, RVTY stock reportedly lost 2.3% since the announcement on Wednesday, while year to date the stock has gained 25%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard